Current Perspectives on Biological Therapy for COPD
Chronic obstructive pulmonary disease (COPD) is a chronic, complex, and heterogeneous condition with significant mortality, morbidity, and socioeconomic burden. Given the heterogeneity, the current management of COPD, which mainly relies on bronchodilators and corticosteroids, cannot consider all CO...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | COPD |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/15412555.2023.2187210 |
| _version_ | 1797404012521193472 |
|---|---|
| author | Ambedkar Kumar Yadav Wenhua Gu Tongyangzi Zhang Xianghuai Xu Li Yu |
| author_facet | Ambedkar Kumar Yadav Wenhua Gu Tongyangzi Zhang Xianghuai Xu Li Yu |
| author_sort | Ambedkar Kumar Yadav |
| collection | DOAJ |
| description | Chronic obstructive pulmonary disease (COPD) is a chronic, complex, and heterogeneous condition with significant mortality, morbidity, and socioeconomic burden. Given the heterogeneity, the current management of COPD, which mainly relies on bronchodilators and corticosteroids, cannot consider all COPD populations. Moreover, the present treatment modalities are directed at minimizing symptoms and reducing the risk of a future attack, but they exhibit few meaningful anti-inflammatory activities in preventing and reducing disease progression. Therefore, new anti-inflammatory molecules are needed to manage COPD better. Use of targeted biotherapy may obtain better results by increasing understanding of the underlying inflammatory process and identifying new biomarkers. In this review, we focus briefly on study of the underlying inflammatory process in the pathogenesis of COPD for better identification of novel target biomarkers, and we describe a novel class of anti-inflammatory biologics that are already under evaluation for their use in managing COPD. |
| first_indexed | 2024-03-09T02:46:56Z |
| format | Article |
| id | doaj.art-096d6fa5b85044d58d4de3ac20606809 |
| institution | Directory Open Access Journal |
| issn | 1541-2555 1541-2563 |
| language | English |
| last_indexed | 2024-03-09T02:46:56Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | COPD |
| spelling | doaj.art-096d6fa5b85044d58d4de3ac206068092023-12-05T16:09:50ZengTaylor & Francis GroupCOPD1541-25551541-25632023-12-0120119720910.1080/15412555.2023.21872102187210Current Perspectives on Biological Therapy for COPDAmbedkar Kumar Yadav0Wenhua Gu1Tongyangzi Zhang2Xianghuai Xu3Li Yu4Department of Pulmonary and Critical Care Medicine, Tongji Hospital, School of Medicine, Tongji UniversityDepartment of Pulmonary and Critical Care Medicine, Tongji Hospital, School of Medicine, Tongji UniversityDepartment of Pulmonary and Critical Care Medicine, Tongji Hospital, School of Medicine, Tongji UniversityDepartment of Pulmonary and Critical Care Medicine, Tongji Hospital, School of Medicine, Tongji UniversityDepartment of Pulmonary and Critical Care Medicine, Tongji Hospital, School of Medicine, Tongji UniversityChronic obstructive pulmonary disease (COPD) is a chronic, complex, and heterogeneous condition with significant mortality, morbidity, and socioeconomic burden. Given the heterogeneity, the current management of COPD, which mainly relies on bronchodilators and corticosteroids, cannot consider all COPD populations. Moreover, the present treatment modalities are directed at minimizing symptoms and reducing the risk of a future attack, but they exhibit few meaningful anti-inflammatory activities in preventing and reducing disease progression. Therefore, new anti-inflammatory molecules are needed to manage COPD better. Use of targeted biotherapy may obtain better results by increasing understanding of the underlying inflammatory process and identifying new biomarkers. In this review, we focus briefly on study of the underlying inflammatory process in the pathogenesis of COPD for better identification of novel target biomarkers, and we describe a novel class of anti-inflammatory biologics that are already under evaluation for their use in managing COPD.http://dx.doi.org/10.1080/15412555.2023.2187210copdbiologicsmanagementnew therapiesanti-inflammatory |
| spellingShingle | Ambedkar Kumar Yadav Wenhua Gu Tongyangzi Zhang Xianghuai Xu Li Yu Current Perspectives on Biological Therapy for COPD COPD copd biologics management new therapies anti-inflammatory |
| title | Current Perspectives on Biological Therapy for COPD |
| title_full | Current Perspectives on Biological Therapy for COPD |
| title_fullStr | Current Perspectives on Biological Therapy for COPD |
| title_full_unstemmed | Current Perspectives on Biological Therapy for COPD |
| title_short | Current Perspectives on Biological Therapy for COPD |
| title_sort | current perspectives on biological therapy for copd |
| topic | copd biologics management new therapies anti-inflammatory |
| url | http://dx.doi.org/10.1080/15412555.2023.2187210 |
| work_keys_str_mv | AT ambedkarkumaryadav currentperspectivesonbiologicaltherapyforcopd AT wenhuagu currentperspectivesonbiologicaltherapyforcopd AT tongyangzizhang currentperspectivesonbiologicaltherapyforcopd AT xianghuaixu currentperspectivesonbiologicaltherapyforcopd AT liyu currentperspectivesonbiologicaltherapyforcopd |